This article was originally published in The Tan Sheet
"Statin therapy should be considered routinely for people across a wider age range and at lower risk of vascular disease than is currently the case," a BMJ online first study published Nov. 10 concludes. At current UK prices, a 40 mg dose of the drug "is likely to be cost saving, or would cost less than £2,500 per life year gained, for people with an annual risk of major vascular events of 1% or more," according to results from the Heart Protection Study Collaborative Group. In the UK, statin treatment is currently recommended for those who have an estimated 10-year risk of a cardiovascular event of 20% or more, the study notes. The trial evaluated 20,356 men and women with coronary disease, other occlusive arterial disease or diabetes in 69 hospitals in the UK. A model was developed to estimate lifetime risks of vascular events and costs of treatment and hospital admissions in the country...
You may also be interested in...
Statins appear to be cost-effective for high-risk, primary-prevention patients who have an absolute 10-year coronary heart disease-event rate of higher than 20%, according to a meta-analysis in the Nov. 27 Archive of Internal Medicine, a JAMA journal
The appointment of Belén Garijo as CEO of the German major from May next year is a small but significant step on the road to addressing gender inequality at the very top level of management in the world of big pharma.
The FDA has published fresh guidance taking a tougher stance on sponsor reasons for needing more time to respond to complete response letters.